Why vaccines to HIV, HCV and Malaria have so far failed - Challenges to developing vaccines against immunoregulating pathogens
Despite continuous progress in the development of anti-viral and anti-bacterial/parasite drugs, the high cost of medicines and the potential for re-infection, especially in high risk groups, suggest that protective vaccines to some of the most dangerous persistent infections are still highly desirab...
Saved in:
Superior document: | Frontiers Research Topics |
---|---|
: | |
Year of Publication: | 2016 |
Language: | English |
Series: | Frontiers Research Topics
|
Physical Description: | 1 electronic resource (157 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993546782304498 |
---|---|
ctrlnum |
(CKB)3800000000216227 (oapen)https://directory.doabooks.org/handle/20.500.12854/62680 (EXLCZ)993800000000216227 |
collection |
bib_alma |
record_format |
marc |
spelling |
Magdalena Plebanski auth Why vaccines to HIV, HCV and Malaria have so far failed - Challenges to developing vaccines against immunoregulating pathogens Frontiers Media SA 2016 1 electronic resource (157 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers Research Topics Despite continuous progress in the development of anti-viral and anti-bacterial/parasite drugs, the high cost of medicines and the potential for re-infection, especially in high risk groups, suggest that protective vaccines to some of the most dangerous persistent infections are still highly desirable. There are no vaccines available for HIV, HCV and Malaria, and all attempts to make a broadly effective vaccine have failed so far. In this Research Topic we look into why vaccines have failed over the years, and what we have learn from these attempts. Rather than only showing positive results, this issue aims to reflect on failed efforts in vaccine development. Coming to understand our limitations will have theoretical and practical implications for the future development of vaccines to these major global disease burdens. English influenza HIV Malaria Infectious Disease Genetics Vaccine HCV immunology 2-88919-966-5 Eric J. Gowans auth Peter Smooker auth Shuo Li auth |
language |
English |
format |
eBook |
author |
Magdalena Plebanski |
spellingShingle |
Magdalena Plebanski Why vaccines to HIV, HCV and Malaria have so far failed - Challenges to developing vaccines against immunoregulating pathogens Frontiers Research Topics |
author_facet |
Magdalena Plebanski Eric J. Gowans Peter Smooker Shuo Li |
author_variant |
m p mp |
author2 |
Eric J. Gowans Peter Smooker Shuo Li |
author2_variant |
e j g ejg p s ps s l sl |
author_sort |
Magdalena Plebanski |
title |
Why vaccines to HIV, HCV and Malaria have so far failed - Challenges to developing vaccines against immunoregulating pathogens |
title_full |
Why vaccines to HIV, HCV and Malaria have so far failed - Challenges to developing vaccines against immunoregulating pathogens |
title_fullStr |
Why vaccines to HIV, HCV and Malaria have so far failed - Challenges to developing vaccines against immunoregulating pathogens |
title_full_unstemmed |
Why vaccines to HIV, HCV and Malaria have so far failed - Challenges to developing vaccines against immunoregulating pathogens |
title_auth |
Why vaccines to HIV, HCV and Malaria have so far failed - Challenges to developing vaccines against immunoregulating pathogens |
title_new |
Why vaccines to HIV, HCV and Malaria have so far failed - Challenges to developing vaccines against immunoregulating pathogens |
title_sort |
why vaccines to hiv, hcv and malaria have so far failed - challenges to developing vaccines against immunoregulating pathogens |
series |
Frontiers Research Topics |
series2 |
Frontiers Research Topics |
publisher |
Frontiers Media SA |
publishDate |
2016 |
physical |
1 electronic resource (157 p.) |
isbn |
2-88919-966-5 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT magdalenaplebanski whyvaccinestohivhcvandmalariahavesofarfailedchallengestodevelopingvaccinesagainstimmunoregulatingpathogens AT ericjgowans whyvaccinestohivhcvandmalariahavesofarfailedchallengestodevelopingvaccinesagainstimmunoregulatingpathogens AT petersmooker whyvaccinestohivhcvandmalariahavesofarfailedchallengestodevelopingvaccinesagainstimmunoregulatingpathogens AT shuoli whyvaccinestohivhcvandmalariahavesofarfailedchallengestodevelopingvaccinesagainstimmunoregulatingpathogens |
status_str |
n |
ids_txt_mv |
(CKB)3800000000216227 (oapen)https://directory.doabooks.org/handle/20.500.12854/62680 (EXLCZ)993800000000216227 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
Frontiers Research Topics |
is_hierarchy_title |
Why vaccines to HIV, HCV and Malaria have so far failed - Challenges to developing vaccines against immunoregulating pathogens |
container_title |
Frontiers Research Topics |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
_version_ |
1787548718059225088 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02001nam-a2200397z--4500</leader><controlfield tag="001">993546782304498</controlfield><controlfield tag="005">20231214133429.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2016 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)3800000000216227</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/62680</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)993800000000216227</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Magdalena Plebanski</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Why vaccines to HIV, HCV and Malaria have so far failed - Challenges to developing vaccines against immunoregulating pathogens</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (157 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Despite continuous progress in the development of anti-viral and anti-bacterial/parasite drugs, the high cost of medicines and the potential for re-infection, especially in high risk groups, suggest that protective vaccines to some of the most dangerous persistent infections are still highly desirable. There are no vaccines available for HIV, HCV and Malaria, and all attempts to make a broadly effective vaccine have failed so far. In this Research Topic we look into why vaccines have failed over the years, and what we have learn from these attempts. Rather than only showing positive results, this issue aims to reflect on failed efforts in vaccine development. Coming to understand our limitations will have theoretical and practical implications for the future development of vaccines to these major global disease burdens.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">influenza</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HIV</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Malaria</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Infectious Disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Genetics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Vaccine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HCV</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunology</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88919-966-5</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Eric J. Gowans</subfield><subfield code="4">auth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Peter Smooker</subfield><subfield code="4">auth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shuo Li</subfield><subfield code="4">auth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:53:50 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2017-09-30 19:47:25 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338297210004498&Force_direct=true</subfield><subfield code="Z">5338297210004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338297210004498</subfield></datafield></record></collection> |